Germany’s Boehringer Ingelheim a patent on HIV drug, Nevirapine, for a version sold as Viramune XR (extended release), has denied by the Indian Patent Office

The application on the Nevirapine extended release formulation was refused on the grounds that it was found to be “obvious” and lacking inventive step, violating Section 3 (d) of the Indian Patent Act. Moreover it was found that Viramune XR was merely a new form of something already known.

>>>read more

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>